

# Enzalutamide

Catalog No: tcsc0317



## Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg

**Size:** 200mg

**Size:** 500mg

**Size:** 1g

**Size:** 2g

**Size:** 5g



## Specifications

**CAS No:**

915087-33-1

**Formula:**

$C_{21}H_{16}F_4N_4O_2S$

**Pathway:**

Others;Autophagy

**Target:**

Androgen Receptor;Autophagy

**Purity / Grade:**

>98%

**Solubility:**

DMSO :  $\geq 50$  mg/mL (107.66 mM); H<sub>2</sub>O :

**Alternative Names:**

MDV3100

**Observed Molecular Weight:**

464.44


**Product Description**

Enzalutamide is an **androgen-receptor (AR)** antagonist with **IC<sub>50</sub>** of 36 nM in LNCaP cells.

IC<sub>50</sub> & Target: IC<sub>50</sub>: 36 nM (androgen-receptor, in LNCaP cells)<sup>[1]</sup>

**In Vitro:** Enzalutamide has greater affinity to AR than Bicalutamide does in a competition assay with 16 $\beta$ -[<sup>18</sup>F]fluoro-5 $\alpha$ -DHT (18-FDHT) in castration-resistant LNCaP/AR cells (AR-overexpressing). While Enzalutamide shows no agonism in LNCaP/AR prostate cells. Enzalutamide antagonizes induction of prostate-specific antigen (PSA) and transmembrane serine protease 2 (TMPRSS2), combination with the synthetic androgen R1881 in parental LNCaP cells. Enzalutamide inhibits the transcriptional activity of a mutant AR protein (W741C, mutation of Trp741 to Cys)<sup>[1]</sup>. Enzalutamide also prevents nuclear translocation and co-activator recruitment of the ligand-receptor complex<sup>[2]</sup>.

**In Vivo:** Enzalutamide induces great tumor regression in castrate male mice bearing LNCaP/AR xenografts at a dose of 10 mg/kg<sup>[1]</sup>. Enzalutamide shows dose-independent pharmacokinetics at intravenous and oral doses of 0.5-5 mg/kg<sup>[4]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!